瑞迈特表示，本次交易为致力于移动氧疗业务的开拓与运营，推动高原氧疗服务的普及与提升。巩固公 司的行业地位和影响力，强化公司的竞争优势、可持续发展能力和核心竞争力，逐步拓展新质生产力。 （文章来源：北京商报） 北京商报讯1月6日晚间，瑞迈特（301367）发布公告称，公司决定以公司自有资金，与关联方成都洛子 科技有限公司、海口润氧共赢企业管理合伙企业（有限合伙）共同投资一家公司，并授权公司管理层办 理该标的公司的投资设立事宜，包括但不限于办理后续出资、签署一切与本次共同投资相关的法律文 件。本次交易完成后，合资公司将纳入公司合并报表范围。 ...

北京商报讯（记者 李晗）2026年1月6日，保利置业披露2025年12月未经审核销售简报。简报显示， 2025年12月保利置业实现合同销售金额约25亿元，合同销售面积约7.1万平方米，合同销售均价约3.56万 元/平方米。 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its associate company, Zhejiang Borui Biopharmaceutical Co., Ltd. (Borui Biopharma), has submitted an application for an initial public offering (IPO) of H-shares on the Hong Kong Stock Exchange on January 6 [2]. Group 1 - Haizheng Pharmaceutical holds a 39.62% stake in Borui Biopharma as of the announcement date [2]. - The IPO application materials were published on the Hong Kong Stock Exchange website on the same day [2].

Core Viewpoint - Shenzhen Hanno Medical Technology Co., Ltd. is the first domestic company to successfully develop and obtain approval for the ECMO system, aiming for an IPO on the Sci-Tech Innovation Board by the end of 2025, despite currently not being profitable and facing significant financial challenges [1][4]. Financial Performance - The total assets of Hanno Medical as of June 30, 2025, are approximately 496.07 million yuan, with a continuous increase in asset-liability ratio, reaching 72.36% [2][10]. - The company reported net profits of -64.79 million yuan in 2022, -341 million yuan in 2023, -182.79 million yuan in 2024, and -82.27 million yuan in the first half of 2025, accumulating losses exceeding 600 million yuan over three and a half years [4][8]. - Operating revenues for the same periods were approximately 0 yuan in 2022, 29.83 million yuan in 2023, 49.31 million yuan in 2024, and 37.35 million yuan in the first half of 2025 [8]. Market Potential - The ECMO market in China is expected to grow significantly, projected to reach 3.71 billion yuan by 2030, with a compound annual growth rate (CAGR) of 25.2% from 2024 to 2030, and 10.73 billion yuan by 2035, with a CAGR of 23.7% from 2030 to 2035 [6]. Challenges in Commercialization - Hanno Medical faces several barriers to the commercialization of its ECMO system, including high technical and cost barriers, market monopolization by imported brands, inadequate clinical training and support systems, and a lengthy profitability cycle due to substantial upfront R&D and market investment [8][9]. IPO and Regulatory Scrutiny - Hanno Medical's IPO application was accepted on December 23, 2025, and the company was selected for on-site inspection as part of the first batch of enterprises for 2026, highlighting the importance of regulatory oversight in ensuring the quality of listed companies [5][11].

北京商报讯(记者王寅浩宋雨盈)1月6日，据首都医科大学附属北京友谊医院消息，该院肝病中心门诊贾 继东主任医师为一位对一线药物应答不佳的原发性胆汁性胆管炎患者开出了有望阻止、延缓疾病进展的 药物Seladelpar。这是中国内地开出的首张处方，也是因北京天竺罕见病药物临床急需临时进口政策获 益的第一位患者。 据了解，Seladelpar是一种强效、高选择性的PPARδ激动剂，能够有效改善胆汁淤积、减轻肝脏炎症和 纤维化，并改善原发性胆汁性胆管炎(PBC)患者的症状和预后，分别于2024年8月、2025年2月于美国及 欧盟上市。借助天竺罕见病保障先行区的政策优势，Seladelpar得以快速获批进入北京友谊医院，为更 多亟需用药的PBC患者提供与国际接轨的前沿治疗。 ...

Core Viewpoint - In December 2025, the company reported a total contract sales amount of approximately 822 million yuan, indicating a significant performance in the real estate market [1] Group 1: Sales Performance - The total contract sales amount for December 2025 was approximately 822 million yuan [1] - The total sales area for the same period was about 66,600 square meters [1] - The average sales price was approximately 12,300 yuan per square meter [1]

北京商报讯(记者李晗)2026年1月6日，融创中国披露2025年12月未经审核经营简报。简报显示，2025年 12月融创中国、附属公司连同合营公司及联营公司实现合同销售金额约29.5亿元，合同销售面积约27.2 万平方米，合同销售均价约1.09万元/平方米。 ...

Core Viewpoint - Zhengrong Real Estate disclosed its unaudited operating brief for December 2025, indicating a total contract sales amount of approximately 335 million yuan and an average contract sales price of about 13,600 yuan per square meter [1] Group 1 - In December 2025, Zhengrong Real Estate, along with its subsidiaries and joint ventures, achieved cumulative contract sales of approximately 335 million yuan [1] - The total contracted sales area for December 2025 was about 24,600 square meters [1] - The average contract sales price for the properties sold was approximately 13,600 yuan per square meter [1]

Core Viewpoint - The Chinese liquor market is showing signs of recovery in 2026, particularly in the high-end and mid-range segments, driven by gifting and banquet demands during the New Year holiday season [1][4][8] Group 1: Market Trends - High-end liquor products, such as Wuliangye and Moutai, are prominently featured in supermarkets and liquor stores, indicating a shift in consumer preferences [4][6] - The price range of 300-500 RMB for mid-range products has become a sales powerhouse during the New Year, reflecting a dual demand from gifting and banquet markets [1][6] - Online channels are also witnessing strong sales of high-end liquor, with significant sales figures reported during live-streaming events [7] Group 2: Consumer Behavior - The liquor market is experiencing a transformation in consumer behavior, with a shift from excessive packaging to more rational consumption patterns [8] - The banquet market remains crucial for liquor sales, with a significant portion of consumption still tied to traditional gifting and business events [9] - The dual recovery in the market reflects both consumer rationality and the maturation of the market, with high-end products stabilizing and mid-range products gaining traction [8][10] Group 3: Future Opportunities - The liquor industry is expected to face a new normal characterized by rational consumption, channel flattening, and intensified competition [10] - Companies need to focus on niche markets and immediate retail channels to capture growth opportunities [10] - The instant retail market is projected to grow significantly, with estimates suggesting a market size of 720 billion RMB by 2025, indicating a competitive landscape for liquor companies [11]

北京商报讯（记者 刘宇阳 实习生 姚榕琰）1月6日，据"华福证券发布"微信公众号信息，当日，华福证券召开董事会会议， 决定董事长黄德良不再兼任公司总裁，聘任蒋松荣为公司总裁。 ...